Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results | Zendy

Joel E. Gallant | Zendy; Ellen Koenig | Zendy; Jaime AndradeVillanueva | Zendy; Ploenchan Chetchotisakd | Zendy; Edwin DeJesus | Zendy; Francisco Antunes | Zendy; Keikawus Arastéh | Zendy; Graeme Moyle | Zendy; Giuliano Rizzardini | Zendy; Jan Fehr | Zendy; Yapei Liu | Zendy; Lijie Zhong | Zendy; Christian Callebaut | Zendy; Javier Szwarcberg | Zendy; Martin S. Rhee | Zendy; Andrew Cheng | Zendy

Open Access

Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results

Author(s) -

Joel E. Gallant,

Ellen Koenig,

Jaime AndradeVillanueva,

Ploenchan Chetchotisakd,

Edwin DeJesus,

Francisco Antunes,

Keikawus Arastéh,

Graeme Moyle,

Giuliano Rizzardini,

Jan Fehr,

Yapei Liu,

Lijie Zhong,

Christian Callebaut,

Javier Szwarcberg,

Martin S. Rhee,

Andrew Cheng

Publication year - 2013

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jit122

Subject(s) - cobicistat , emtricitabine , atazanavir , medicine , ritonavir , discontinuation , tolerability , elvitegravir , adverse effect , tenofovir alafenamide , viral load , lopinavir , gastroenterology , pharmacology , human immunodeficiency virus (hiv) , virology , antiretroviral therapy

Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research